Product nameAnti-Mkl1/MRTFA antibody
See all Mkl1/MRTFA primary antibodies
DescriptionRabbit polyclonal to Mkl1/MRTFA
This antibody is specific for Mkl1/MRTFA.
Tested applicationsSuitable for: ICC/IF, IP, WB, ELISAmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat, Rabbit, Horse, Cow, Cat, Dog, Pig
- WB: NIH3T3 lysate. ICC/IF MEF1 and HeLa cells.
This product was previously labelled as Mkl1
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 2% Sucrose, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab49311 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 10 µg/ml.|
|IP||Use at an assay dependent concentration. PubMed: 23243284|
|WB||Use a concentration of 1.25 µg/ml. Detects a band of approximately 109 kDa (predicted molecular weight: 99 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.|
|ELISA||Use at an assay dependent concentration.
ELISA titre using peptide based assay: 1:1562500.
FunctionTranscriptional coactivator of serum response factor (SRF) with the potential to modulate SRF target genes. Suppresses TNF-induced cell death by inhibiting activation of caspases; its transcriptional activity is indispensable for the antiapoptotic function. It may up-regulate antiapoptotic molecules, which in turn inhibit caspase activation.
Tissue specificityUbiquitously expressed, has been detected in lung, placenta, small intestine, liver, kidney, spleen, thymus, colon, muscle, heart and brain.
Involvement in diseaseNote=A chromosomal aberration involving MKL1 may be a cause of acute megakaryoblastic leukemia. Translocation t(1;22)(p13;q13) with RBM15. Although both reciprocal fusion transcripts are detected in acute megakaryoblastic leukemia (AMKL, FAB-M7), the RBM15-MKL1 chimeric protein has all the putative functional domains encoded by each gene and is the candidate oncogene.
Sequence similaritiesContains 2 RPEL repeats.
Contains 1 SAP domain.
DomainThe N-terminal region is required for nuclear localization and the C-terminal region mediates transcriptional activity.
The RPEL repeats mediate binding to globular actin.
Cellular localizationCytoplasm. Nucleus. Binding to globular actin is required to maintain cytoplasmic localization.
- Information by UniProt
- AI852829 antibody
- AMKL antibody
- AW743281 antibody
Anti-Mkl1/MRTFA antibody (ab49311) at 1.25 µg/ml + NIH3T3 lysate at 10 µg
HRP conjugated anti-Rabbit IgG at 1/50000 dilution
Predicted band size: 99 kDa
Observed band size: 109 kDa why is the actual band size different from the predicted?
ICC/IF image of ab49311 stained MEF1 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab49311, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Paraformaldehyde-fixed, 0.3% Triton X100 permeabilized HeLa (humanepithelial cell line from cervix adenocarcinoma) cells stained for Mkl1/MRTFA (red) using ab49311 at 1/150 dilution in ICC/IF, followed by Goat anti Rabbit Cy3 secondary antibody at 1/100 dilution.
This product has been referenced in:
- Montel L et al. The nature and intensity of mechanical stimulation drive different dynamics of MRTF-A nuclear redistribution after actin remodeling in myoblasts. PLoS One 14:e0214385 (2019). Read more (PubMed: 30921405) »
- Fiore VF et al. avß3 Integrin drives fibroblast contraction and strain stiffening of soft provisional matrix during progressive fibrosis. JCI Insight 3:N/A (2018). Read more (PubMed: 30333317) »